USPTO serial 79281569
BACHEM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 7, 2022
- Examiner
- CIANCI, RYAN MICHAEL
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BACHEM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sarah M. Robertson
Sarah M. Robertson Dorsey & Whitney LLP51 West 52nd StreetNew York, NY 10019-6119UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry and science; chemical preparations for scientific use; chemical preparations for use in industry; industrial chemicals; reagents for research purposes; reagents for scientific use; chemical preparations for scientific use, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary use; chemicals for industry; chemical reagents for scientific use; peptides for use in industry and science; proteins for use in industry and science; oligonucleotides for use in industry and science; oligopeptides for industrial use; proteins for industrial use; proteins for use in manufacture; amino acids for industrial use; amino acids for scientific use; peptide substrates for scientific use; chemical preparations for use in the manufacture of cosmetics; peptides for use in the manufacture of cosmetics; proteins for use in the manufacture of cosmetics; oligonucleotides for use in the manufacture of cosmetics; chemical preparations for use in the production of medicines; chemical preparations for use in the manufacture of pharmaceuticals; peptides for use in the manufacture of pharmaceuticals; proteins for use in the manufacture of pharmaceuticals; oligonucleotides for use in the manufacture of pharmaceuticals; chemical reagents for use in genetic research; chemicals for use in biotechnological manufacturing processes; chemicals for use in biotechnological product development; active chemical ingredients for use in the manufacture of anti-cancer drugs; active chemical ingredients for use in the manufacture of anti-diabetes drugs; active chemical ingredients for use in the manufacture of drugs against metabolic diseases; active chemical ingredients for use in the manufacture of drugs for wound healing; active chemical ingredients for use in the manufacture of drugs against genetic diseases; active chemical ingredients for use in the manufacture of drugs against neurological diseases; amides for use in manufacture; chemical additives for use in the manufacture of cosmetics; chemical additives for use in the manufacture of medicines; chemical additives for use in the manufacture of pharmaceuticals; diagnostic preparations for scientific or research use; diagnostic preparations, other than for medical or veterinary use; diagnostic reagents for scientific or research use; diagnostic reagents, other than for medical or veterinary use; biological preparations for use in industry and science; biological preparations, other than for medical or veterinary use; adjuvants, other than for medical or veterinary purposes; biochemical catalysts; biochemical preparations for scientific use; biochemicals for in vitro and in vivo scientific use; emollients for industrial use; emollients for use in the manufacture of cosmetics; emollients for use in the manufacture of pharmaceuticals; enzyme stabilizers; enzyme substrates; phosphoproteins | ACTIVE | — |
| 005 | Chemical reagents for medical or veterinary use; reagents for medical use; peptides for medical use; protein arrays for medical diagnostic use; oligonucleotides for medical use; amino acids for medical use; peptides for pharmaceutical use; synthetic peptides for pharmaceutical use; peptides for veterinary use; amino acids for veterinary use; diagnostic preparations for medical use; diagnostic preparations for veterinary use; biological and pharmaceutical preparations for diagnostic purposes; diagnostic test reagents for medical or veterinary use; peptides for diagnostic purposes; proteins for diagnostic purposes; oligonucleotides for diagnostic purposes; diagnostic kits containing diagnostic agents, preparations and substances for medical use; chemical preparations for the diagnosis of pregnancy; biological and chemical reagents for medical or veterinary use; biological preparations for diagnostic purposes; pharmaceutical preparations against metabolic diseases; pharmaceutical preparations for wound healing; pharmaceutical preparations against genetic diseases; pharmaceutical preparations against neurological diseases; biological reagents for medical use; biological reagents for veterinary use; adjuvants for medical use; adjuvants for veterinary use; anti-bacterial preparations for medical purposes; anti-cancer preparations; antitumor drugs; biopharmaceutical anti-tumor medicines; biopharmaceuticals for the treatment of cancer; anti-diabetic preparations; chemotherapeutics; cosmeceuticals for therapeutic or medical use, namely, medicated soap; dermatological preparations; diagnostic biomarker reagents for medical use; food supplements with cosmetic effect; dietetic preparations adapted for medical use; dietetic preparations adapted for veterinary use; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; in vitro diagnostic preparations for medical use; medical diagnostic reagents and assays for testing of body fluids; nucleic acid sequences for medical and veterinary use; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals; custom manufacture of biopharmaceuticals; custom manufacturing of peptides; custom manufacturing of proteins; custom manufacturing of oligonucleotides; processing of chemicals; processing of chemical reagents; processing of peptides; processing of proteins; processing of oligonucleotides; processing of medicinal materials; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials | ACTIVE | — |
| 042 | Scientific research; chemical research; chemical engineering; product research and development; research and development of new products for others; research and development services in the field of chemistry; research and development in the field of peptides; research and development in the field of proteins; research and development in the field of oligonucleotides; research and development services for the pharmaceutical industry; research and development services in the field of pharmaceutical preparations; research and development services in the field of biochemistry; research and development services in the field of cosmetics; research and development services in the field of diagnostic preparations; research and development services in the field of gene expression systems; research in the fields of chemistry and biology; development of methods of manufacture for peptides, proteins, oligonucleotides, pharmaceuticals, and cosmetics; development of analytic methods for developing for peptides, proteins, oligonucleotides, pharmaceuticals, and cosmetics; scientific laboratory services; chemical analysis; chemical, biochemical, biological and bacteriological research and analysis; analysis in the form of research in the field of molecular biology; conducting of scientific feasibility studies; providing information in the form of preparation of reports relating to scientific research; quality control; product testing; advisory services relating to material testing; consultancy in the field of biochemistry research; consultancy in the field of chemistry research; consultancy in the field of scientific and industrial research; consultancy relating to laboratory testing research; consulting services in the field of recombinant DNA technology research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Bachem Holding AG
- Other trademarks owned by Bachem Holding AG
- Other trademarks owned by Bachem Holding AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named BACHEM
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 30, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 10, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 19, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 19, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 7, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 7, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 7, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 29, 2022 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Apr 1, 2022 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Feb 15, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 15, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 13, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 26, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 26, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 26, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 11, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 8, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 7, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 7, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 19, 2021 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 1, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 1, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 7, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 7, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 7, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 25, 2021 | LIME | LIMITATION FROM THE IB - REQUEST EXAM REVIEW | — |
| Feb 24, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 24, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 24, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 29, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 29, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 28, 2021 | ALIE | ASSIGNED TO LIE | — |
| Nov 27, 2020 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Oct 19, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 9, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 18, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 18, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 3, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 3, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 2, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 30, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 30, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 26, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |